Switching antipsychotics to partial dopamine D2-agonists in individuals affected by schizophrenia: a narrative review

References

• Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Moller, H. J., Allgulander, C., Ayuso-Gutierrez, J., Baldwin, D. S., Buenvicius, R., Cassano, G., Fineberg, N., Gabriels, L., Hindmarch, I., Kaiya, H., Klein, D. F., Lader, M., Lecrubier, Y., Lepine, J. P., Liebowitz, M. R., … Vega, J, WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disoders (2008). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry, 9(4), 248–312. doi:10.1080/15622970802465807.
   PubMed Web of Science ®Google Scholar
• Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., Joyce, E. M., Lewis, S., Lingford-Hughes, A., MacCabe, J. H., Owens, D. C., Patel, M. X., Sinclair, J. M., Stone, J. M., Talbot, P. S., … Yung, A. R. (2020). Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 34(1), 3–78. doi:10.1177/0269881119889296.
   PubMed Web of Science ®Google Scholar
• Bernardo, M., Rico-Villademoros, F., Garcia-Rizo, C., Rojo, R., & Gomez-Huelgas, R. (2021). Real-world data on the adverse metabolic effects of second-generation antipsychotics and their potential determinants in adult patients: a systematic review of population-based studies. Advances in Therapy, 38(5), 2491–2512. doi:10.1007/s12325-021-01689-8.
   PubMed Web of Science ®Google Scholar
• Buckley, P. F., & Correll, C. U. (2008). Strategies for dosing and switching antipsychotics for optimal clinical management. The Journal of Clinical Psychiatry, 69(Suppl 1), 4–17.
   Google Scholar
• Casey, D. E., Carson, W. H., Saha, A. R., Liebeskind, A., Ali, M. W., Jody, D., & Ingenito, G. G, Aripiprazole Study G (2003). Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology, 166(4), 391–399. doi:10.1007/s00213-002-1344-3.
   PubMed Web of Science ®Google Scholar
• Chen, Y., Bobo, W. V., Watts, K., Jayathilake, K., Tang, T., & Meltzer, H. Y. (2012). Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study. Journal of Psychopharmacology, 26(9), 1201–1210. doi:10.1177/0269881111430748.
   PubMed Web of Science ®Google Scholar
• Chue, P., Stip, E., Remington, G., & Kopala, L. (2004). Switching atypical antipsychotics: a review. Acta Neuropsychiatrica, 16(6), 301–313. doi:10.1111/j.0924-2708.2004.00098.x.
   PubMed Web of Science ®Google Scholar
• Citrome, L. (2015). The ABC’s of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out. International Journal of Clinical Practice, 69(11), 1211–1220. doi:10.1111/ijcp.12752.
   PubMed Web of Science ®Google Scholar
• Correll, C. U., Shi, L., Weiss, C., Hobart, M., Eramo, A., Duffy, R. A., Weiller, E., & Baker, R. A. (2019). Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians’ choice of cross-titration schedules in a post hoc analysis of a randomized, double-blind, maintenance treatment study. CNS Spectrums, 24(5), 507–517. doi:10.1017/S1092852918001086.
   PubMed Web of Science ®Google Scholar
• Duque-Yemail, J. D., & Avila, J. C. (2022). Switching Clozapine to Cariprazine in Three Patients with Persistent Symptoms of Schizophrenia: a Case Series. Neuropsychiatric Disease and Treatment, 18, 1433–1440. doi:10.2147/NDT.S367922.
   PubMed Web of Science ®Google Scholar
• Durgam, S., Cutler, A. J., Lu, K., Migliore, R., Ruth, A., Laszlovszky, I., Nemeth, G., & Meltzer, H. Y. (2015). Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. The Journal of Clinical Psychiatry, 76(12), e1574-1582–e1582. doi:10.4088/JCP.15m09997.
   Web of Science ®Google Scholar
• Durgam, S., Earley, W., Li, R., Li, D., Lu, K., Laszlovszky, I., Fleischhacker, W. W., & Nasrallah, H. A. (2016). Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. Schizophrenia Research, 176(2-3), 264–271. doi:10.1016/j.schres.2016.06.030.
   PubMed Web of Science ®Google Scholar
• Durgam, S., Litman, R. E., Papadakis, K., Li, D., Nemeth, G., & Laszlovszky, I. (2016). Cariprazine in the treatment of schizophrenia: a proof-of-concept trial. International Clinical Psychopharmacology, 31(2), 61–68. doi:10.1097/YIC.0000000000000110.
   PubMed Web of Science ®Google Scholar
• Durgam, S., Starace, A., Li, D., Migliore, R., Ruth, A., Nemeth, G., & Laszlovszky, I. (2014). An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophrenia Research, 152(2-3), 450–457. doi:10.1016/j.schres.2013.11.041.
   PubMed Web of Science ®Google Scholar
• Edlinger, M., Baumgartner, S., Eltanaihi-Furtmuller, N., Hummer, M., & Fleischhacker, W. W. (2005). Switching between second-generation antipsychotics: why and how? CNS Drugs, 19(1), 27–42. doi:10.2165/00023210-200519010-00003.
   PubMed Web of Science ®Google Scholar
• Fagiolini, A., Brugnoli, R., Di Sciascio, G., De Filippis, S., & Maina, G. (2015). Switching antipsychotic medication to aripiprazole: position paper by a panel of Italian psychiatrists. Expert Opinion on Pharmacotherapy, 16(5), 727–737. doi:10.1517/14656566.2015.1013029.
   PubMed Web of Science ®Google Scholar
• Fagiolini, A., Alcala, J. A., Aubel, T., Bienkiewicz, W., Bogren, M. M. K., Gago, J., Cerveri, G., Colla, M., Sanchez, F. C., Cuomo, A., Helge, F., Iacoponi, E., Karlsson, P. A., Peddu, P., Pettorruso, M., Pereira, H. J. R., Scholin, J. S., & Vernaleken, I. B. (2020). Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel. Annals of General Psychiatry, 19, 55.
   PubMed Web of Science ®Google Scholar
• Fleischhacker, W. W., Hobart, M., Ouyang, J., Forbes, A., Pfister, S., McQuade, R. D., Carson, W. H., Sanchez, R., Nyilas, M., & Weiller, E. (2017). Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study. The International Journal of Neuropsychopharmacology, 20(1), 11–21. doi:10.1093/ijnp/pyw076.
   PubMed Web of Science ®Google Scholar
• Fraguas, D., Almenta Gallego, D., Arques-Egea, S., Gomez-Revuelta, M., Sanchez-Lafuente, C. G., Hernandez Huerta, D., Nunez Arias, D., Oda Plasencia-Garcia, B., Parro Torres, C., Romero-Guillena, S. L., Ros Cucurul, E., & Alamo, C. (2022). Aripiprazole for the treatment of schizophrenia: recommendations of a panel of Spanish experts on its use in clinical practice. International Journal of Psychiatry in Clinical Practice 27(1):82–91.
   PubMed Web of Science ®Google Scholar
• Ganguli, R. (2002). Rationale and strategies for switching antipsychotics. American Journal of Health-System Pharmacy : AJHP : official Journal of the American Society of Health-System Pharmacists, 59(22 Suppl 8), S22–S26. doi:10.1093/ajhp/59.suppl_8.S22.
   PubMedGoogle Scholar
• Hart, X. M., Schmitz, C. N., & Grunder, G. (2022). Molecular imaging of dopamine partial agonists in humans: Implications for clinical practice. Frontiers in Psychiatry, 13, 832209. doi:10.3389/fpsyt.2022.832209.
   PubMed Web of Science ®Google Scholar
• Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., & Moller, H. J, World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for S (2012). World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry, 13(5), 318–378. doi:10.3109/15622975.2012.696143.
   PubMed Web of Science ®Google Scholar
• Hatta, K., Sugiyama, N., & Ito, H. (2018). Switching and augmentation strategies for antipsychotic medications in acute-phase schizophrenia: latest evidence and place in therapy. Therapeutic Advances in Psychopharmacology, 8(6), 173–183. doi:10.1177/2045125318754472.
   PubMed Web of Science ®Google Scholar
• Hiemke, C., Bergemann, N., Clement, H. W., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., Grunder, G., Haen, E., Havemann-Reinecke, U., Hefner, G., Helmer, R., Janssen, G., Jaquenoud, E., Laux, G., Messer, T., & Baumann, P. (2018). Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry, 51(1/2), 9–62.
   PubMed Web of Science ®Google Scholar
• Hwang, T. J., Lo, W. M., Chan, H. Y., Lin, C. F., Hsieh, M. H., Liu, C. C., Liu, C. M., Hwu, H. G., Kuo, C. H., & Chen, W. J. (2015). Fast versus slow strategy of switching patients with schizophrenia to aripiprazole from other antipsychotics. Journal of Clinical Psychopharmacology, 35(6), 635–644. doi:10.1097/JCP.0000000000000426.
   PubMed Web of Science ®Google Scholar
• Ichinose, M., Miura, I., Horikoshi, S., Yamamoto, S., Kanno-Nozaki, K., Watanabe, K., & Yabe, H. (2021). Effect of switching to brexpiprazole on plasma homovanillic acid levels and antipsychotic-related side effects in patients with schizophrenia or schizoaffective disorder. Neuropsychiatric Disease and Treatment, 17, 1047–1053. doi:10.2147/NDT.S306573.
   PubMed Web of Science ®Google Scholar
• Ishigooka, J., Inada, K., Niidome, K., Aoki, K., Kojima, Y., Iwashita, S., & Yamada, S. (2021). Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post-hoc analysis of a long-term open-label study. Human Psychopharmacology., 36(4), e2777.
   PubMed Web of Science ®Google Scholar
• Ishigooka, J., Iwashita, S., & Tadori, Y. (2018). Long-term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: A 52-week, open-label study. Psychiatry and Clinical Neurosciences, 72(6), 445–453. doi:10.1111/pcn.12654.
   PubMed Web of Science ®Google Scholar
• Ishigooka, J., Usami, T., Iwashita, S., Kojima, Y., & Matsuo, S. (2020). Post-hoc analysis investigating the safety and efficacy of brexpiprazole in Japanese patients with schizophrenia who were switched from other antipsychotics in a long-term study (Secondary Publication). Neuropsychopharmacology Reports, 40(2), 122–129. doi:10.1002/npr2.12107.
   PubMed Web of Science ®Google Scholar
• Kaiser, S., Berger, G., Conus, P., Kawohl, W., Müller, T. J., Schimmelmann, B. G., Traber, R., Trächsel, N., Vauth, R., & Seifritz, E. (2016). SGPP Behandlungsempfehlungen Schizophrenie. Psy & Psy.
   Google Scholar
• Keks, N., Schwartz, D., & Hope, J. (2019). Stopping and switching antipsychotic drugs. Australian Prescriber, 42(5), 152–157. doi:10.18773/austprescr.2019.052.
   PubMed Web of Science ®Google Scholar
• Kim, C. Y., Chung, S., Lee, J. N., Kwon, J. S., Kim, D. H., Kim, C. E., Jeong, B., Jeon, Y. W., Lee, M. S., Jun, T. Y., & Jung, H. Y. (2009). A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder. International Clinical Psychopharmacology, 24(4), 181–188. doi:10.1097/YIC.0b013e32832c25d7.
   PubMed Web of Science ®Google Scholar
• Lambert, T. J. (2007). Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. Journal of Clinical Psychiatry, 68(Suppl 6), 10–13.
   PubMedGoogle Scholar
• Lin, H. C., Chong, M. Y., Lee, Y., Yeh, W. C., & Lin, P. Y. (2009). Switching of antipsychotics to aripiprazole in the treatment of schizophrenia. Chang Gung Medical Journal, 32(4), 409–416.
   PubMedGoogle Scholar
• Masand, P. S. (2005). A review of pharmacologic strategies for switching to atypical antipsychotics. Primary Care Companion to the Journal of Clinical Psychiatry, 7(3), 121–129.
   PubMedGoogle Scholar
• Mohr, P., Masopust, J., & Kopecek, M. (2021). Dopamine receptor partial agonists: do they differ in their clinical efficacy? Frontiers in Psychiatry, 12, 781946. doi:10.3389/fpsyt.2021.781946.
   PubMed Web of Science ®Google Scholar
• Nemeth, G., Laszlovszky, I., Czobor, P., Szalai, E., Szatmari, B., Harsanyi, J., Barabassy, A., Debelle, M., Durgam, S., Bitter, I., Marder, S., & Fleischhacker, W. W. (2017). Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet, 389(10074), 1103–1113. doi:10.1016/S0140-6736(17)30060-0.
   PubMed Web of Science ®Google Scholar
• Newcomer, J. W., Weiden, P. J., & Buchanan, R. W. (2013). Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice. The Journal of Clinical Psychiatry, 74(11), 1108–1120. doi:10.4088/JCP.12028ah1.
   PubMed Web of Science ®Google Scholar
• Obayashi, Y., Mitsui, S., Sakamoto, S., Minao, N., Yoshimura, B., Kono, T., Yada, Y., Okahisa, Y., Takao, S., Kishi, Y., Takeda, T., Takaki, M., & Yamada, N. (2020). Switching strategies for antipsychotic monotherapy in schizophrenia: a multi-center cohort study of aripiprazole. Psychopharmacology, 237(1), 167–175. doi:10.1007/s00213-019-05352-7.
   PubMed Web of Science ®Google Scholar
• Pae, C. U., Serretti, A., Chiesa, A., Mandelli, L., Lee, C., Lee, C., Kim, J., De Ronchi, D., & Paik, I. H. (2009). Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology, 19(8), 562–570. doi:10.1016/j.euroneuro.2009.04.002.
   PubMed Web of Science ®Google Scholar
• Pillinger, T., McCutcheon, R. A., Vano, L., Mizuno, Y., Arumuham, A., Hindley, G., Beck, K., Natesan, S., Efthimiou, O., Cipriani, A., & Howes, O. D. (2020). Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. The Lancet Psychiatry, 7(1), 64–77. doi:10.1016/S2215-0366(19)30416-X.
   PubMed Web of Science ®Google Scholar
• Rancans, E., Dombi, Z. B., & Barabassy, A. (2021). Dosing cariprazine within and beyond clinical trials: recommendations for the treatment of schizophrenia. Frontiers in Psychiatry, 12, 770234. doi:10.3389/fpsyt.2021.770234.
   PubMed Web of Science ®Google Scholar
• Rossi, A., Canas, F., Fagiolini, A., Larmo, I., Levy, P., Montes, J. M., Papageorgiou, G., Sturlason, R., Zink, M., & Correll, C. U. (2011). Switching among antipsychotics in everyday clinical practice: focus on ziprasidone. Postgraduate Medicine, 123(1), 135–159. doi:10.3810/pgm.2011.01.2255.
   PubMed Web of Science ®Google Scholar
• Ryckmans, V., Kahn, J. P., Modell, S., Werner, C., McQuade, R. D., Kerselaers, W., Lissens, J., & Sanchez, R. (2009). Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study. Pharmacopsychiatry, 42(3), 114–121. doi:10.1055/s-0028-1112134.
   PubMed Web of Science ®Google Scholar
• Schoretsanitis, G., Kane, J. M., Correll, C. U., Marder, S. R., Citrome, L., Newcomer, J. W., Robinson, D. G., Goff, D. C., Kelly, D. L., Freudenreich, O., Piacentino, D., Paulzen, M., Conca, A., Zernig, G., Haen, E., Baumann, P., Hiemke, C., & Grunder, G, American Society of Clinical P, Pharmakopsychiatrie T (2020). Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the american society of clinical psychopharmacology and the therapeutic drug monitoring task force of the arbeitsgemeinschaft fur neuropsychopharmakologie und pharmakopsychiatrie. The Journal of Clinical Psychiatry, 81(3), 19cs13169. doi:10.4088/JCP.19cs13169.
   PubMed Web of Science ®Google Scholar
• Stahl, S. M. (2013). Stahl’s essential psychopharmacology: neuroscientific basis and practical application. Cambridge University Press.
   Google Scholar
• Stahl, S. B., Stahl, S. M., editor. (2020). Prescriber’s guide: Stahl’s essential psychopharmacology. Cambridge University Press. p. 103–110.
   Google Scholar
• Stroup, T. S., McEvoy, J. P., Ring, K. D., Hamer, R. H., LaVange, L. M., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Nussbaum, A. M., & Lieberman, J. A, Schizophrenia Trials N (2011). A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). The American Journal of Psychiatry, 168(9), 947–956. doi:10.1176/appi.ajp.2011.10111609.
   PubMed Web of Science ®Google Scholar
• Takeuchi, H., Kantor, N., Uchida, H., Suzuki, T., & Remington, G. (2017a). Immediate vs gradual discontinuation in antipsychotic switching: a systematic review and meta-analysis. Schizophr Bull, 43(4), 862–871.
   PubMed Web of Science ®Google Scholar
• Takeuchi, H., & Remington, G. (2020). Immediate versus wait-and-gradual discontinuation in antipsychotic switching: A meta-analysis. Journal of Psychopharmacology (Oxford, England), 34(8), 914–919. doi:10.1177/0269881120922964.
   PubMed Web of Science ®Google Scholar
• Takeuchi, H., Suzuki, T., Uchida, H., Nakajima, S., Nomura, K., Kikuchi, T., Manki, H., Watanabe, K., & Kashima, H. (2008). A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering. Journal of Clinical Psychopharmacology, 28(5), 540–543. doi:10.1097/JCP.0b013e3181842586.
   PubMed Web of Science ®Google Scholar
• Takeuchi, H., Thiyanavadivel, S., Agid, O., & Remington, G. (2017b). Gradual vs. wait-and-gradual discontinuation in antipsychotic switching: A meta-analysis. Schizophrenia Research, 189, 4–8. doi:10.1016/j.schres.2017.02.011.
   PubMed Web of Science ®Google Scholar
• Takeuchi, H., Thiyanavadivel, S., Agid, O., & Remington, G. (2018). Rapid vs. slow antipsychotic initiation in schizophrenia: A systematic review and meta-analysis. Schizophrenia Research, 193, 29–36. doi:10.1016/j.schres.2017.08.012.
   PubMed Web of Science ®Google Scholar
• Taylor, D., Chithiramohan, R., Grewal, J., Gupta, A., Hansen, L., Reynolds, G. P., & Pappa, S. (2022). Dopamine partial agonists: a discrete class of antipsychotics. International Journal of Psychiatry in Clinical Practice, 10, 1–13. doi:10.1080/13651501.2022.2151473.
   Google Scholar
• Veznedaroglu, B., Dilbaz, N., Uzun, O., & Isik, E. (2018). TARC: turkish aripiprazole consensus report- Aripiprazole use and switching from other antipsychotics to aripiprazole- consensus recommendations by a Turkish multidisciplinary panel. Therapeutic Advances in Psychopharmacology, 8(10), 271–285. doi:10.1177/2045125318772712.
   PubMed Web of Science ®Google Scholar
• Weiden, P. J. (2006). Switching in the era of atypical antipsychotics. An updated review. Postgraduate Medicine, Spec No, 27–44.
   PubMedGoogle Scholar